Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Immutep (IMMP)
NASDAQ:IMMP
Holding IMMP?
Track your performance easily
IMMP Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.58 - $3.34
Previous Close$1.84
Volume61.71K
Average Volume (3M)113.22K
Market Cap
$261.60M
Enterprise Value$142.77M
Total Cash (Recent Filing)AU$181.88M
Total Debt (Recent Filing)AU$1.59M
Price to Earnings (P/E)―
Beta1.83
Next Earnings
Feb 20, 2025EPS Estimate
-$0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.23
Shares Outstanding145,456,785
10 Day Avg. Volume72,593
30 Day Avg. Volume113,220
Standard Deviation0.21
R-Squared0.29
Alpha-0.00156
Financial Highlights & Ratios
Price to Book (P/B)1.43
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$8.00Price Target Upside331.27% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Immutep News
PremiumCompany Announcements
Immutep’s Growth and Advancements Boost Market Visibility
PremiumCompany Announcements
Immutep Advances Breast Cancer Immunotherapy Trial
PremiumCompany Announcements
Immutep’s Efti Shows Promise in Cancer TherapyBulls Say, Bears Say
Bulls Say
Clinical TrialsThe efti/pembro combination has shown a dramatic improvement in median overall survival over the standard of care in a major study, indicating its potential impact on cancer treatment.
Market PotentialImmutep's focus on developing LAG-3 for multiple oncology indications, combined with a market cap of $364MM, suggests considerable upside potential for its shares.
Product DevelopmentThe company's lead product candidate, eftilagimod alpha (efti), is a promising soluble LAG-3 for advanced cancers, providing innovative treatment options.
Bears Say
Competitive EnvironmentThe 1L metastatic HNSCC space has become very competitive.
Efficacy ConcernsIt is unclear whether the combination can show enough efficacy to make its way into what appears to be a highly competitive and potentially crowded setting.
Study ResultsThe randomized arm of TACTI-003 is viewed as a 'failed study' due to the lack of a clear go/no go signal for Phase 3.
---
Ownership Overview
―
Insiders
0.02% Mutual Funds
0.11% Other Institutional Investors
99.21% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IMMP FAQ
What was Immutep’s price range in the past 12 months?
Immutep lowest stock price was $1.58 and its highest was $3.33 in the past 12 months.
What is Immutep’s market cap?
Currently, no data Available
When is Immutep’s upcoming earnings report date?
Immutep’s upcoming earnings report date is Feb 20, 2025 which is in 103 days.
How were Immutep’s earnings last quarter?
Immutep released its earnings results on Aug 28, 2024. The company reported -$0.121 earnings per share for the quarter, beating the consensus estimate of -$0.125 by $0.004.
Is Immutep overvalued?
According to Wall Street analysts Immutep’s price is currently Undervalued.
Does Immutep pay dividends?
Immutep does not currently pay dividends.
What is Immutep’s EPS estimate?
Immutep’s EPS estimate is -$0.15.
How many shares outstanding does Immutep have?
Immutep has 145,456,790 shares outstanding.
What happened to Immutep’s price movement after its last earnings report?
Immutep reported an EPS of -$0.121 in its last earnings report, beating expectations of -$0.125. Following the earnings report the stock price went up 5.021%.
Which hedge fund is a major shareholder of Immutep?
Among the largest hedge funds holding Immutep’s share is Oracle Investment Management Inc. It holds Immutep’s shares valued at N/A.
---
Immutep Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.00 (331.27% Upside)
$8.00 (331.27% Upside)
Blogger Sentiment
Bullish
IMMP Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 564.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 1.6%
Last 30 Days ▲ 1.3%
Last 30 Days ▲ 1.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-1.60%
12-Months-Change
Fundamentals
Return on Equity
-25.75%
Trailing 12-Months
Asset Growth
37.16%
Trailing 12-Months
Company Description
Immutep
Immutep Ltd. is a biotechnology company, which engages in the research and development of immunotherapeutic treatments for cancer and autoimmune diseases. Its product is IMP321, which involves in clinical development for the treatment of breast cancer and melanoma. The company was founded on May 21, 1987 and is headquartered in Sydney, Australia.
---
IMMP Stock 12 Month Forecast
Average Price Target
$8.00
▲(331.27% Upside)
Technical Analysis
Best Analysts Covering IMMP
1 Year
1 Year Success Rate
0/11 ratings generated profit
1 Year Average Return
-37.26%
reiterated a buy rating 2 months ago
Copying Naureen Quibria's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -37.26% per trade.
---